

INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

ICH HARMONISED GUIDELINE

BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED

BIOWAIVERS

M9

Draft version

Endorsed on 7 June 2018

Currently under public consultation

At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

M9 Document History

Code	History	Date
M9	Endorsement by the Members of the ICH	7 June 2018
	Assembly under <i>Step 2</i> and release for public	
	consultation (document dated 6 June 2018).	

Legal notice: This document is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided.

The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.

The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

ICH HARMONISED GUIDELINE

BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED

BIOWAIVERS

M9

ICH Consensus Guideline

TABLE OF CONTENTS

1.	Introduction	. 1
	1.1. Background and Objective	1
	1.2 Scope	. 1
2.	Biopharmaceutics classification of the drug substance	. 2
	2.1. Solubility	. 2
	2.2. Permeability	. 3
3.	Support of the eligibility of a drug product for a BCS-based biowaiver	. 4
	3.1. Excipients	. 4
	3.2. In vitro dissolution	. 6
4.	Documentation	. 8
5.	Glossary	. 9

1 INTRODUCTION

2 1.1. Background and Objective

Two drug products containing the same active substance are considered bioequivalent if their bioavailabilities (rate and extent of drug absorption) after administration in the same molar dose lie within acceptable predefined limits. These limits are set to ensure comparable *in vivo* performance, i.e., similarity in terms of safety and efficacy. In *in vivo* bioequivalence studies, the pivotal pharmacokinetic parameters AUC (the area under the concentration time curve), and C_{max} (the maximum concentration), are generally used to assess the rate and extent of drug absorption.

The BCS (Biopharmaceutics Classification System)-based biowaiver approach is intended to 10 reduce the need for in vivo bioequivalence studies i.e., it can provide a surrogate for in vivo 11 bioequivalence. In vivo bioequivalence studies may be exempted if an assumption of 12 13 equivalence in *in vivo* performance can be justified by satisfactory *in vitro* data. The BCS is a 14 scientific approach based on the aqueous solubility and intestinal permeability characteristics of the drug substance. The BCS categorizes drug substances into one of four BCS classes as 15 follows: 16 Class I: high solubility, high permeability 17

- 18 Class II: low solubility, high permeability
- 19 Class III: high solubility, low permeability
- 20 Class IV: low solubility, low permeability
- 21 This guidance will provide recommendations to support the biopharmaceutics classification of
- 22 drug substances and the BCS-based biowaiver of bioequivalence studies for drug products.

23 **1.2 Scope**

BCS-based biowaivers may be used to demonstrate bioequivalence for example between products used in early clinical development through commercialization, for line extensions of the same pharmaceutical form of innovator products, in applications for generic drug products, and post-approval changes that would otherwise require *in vivo* bioequivalence evaluation, in accordance with regional regulations.

The BCS-based biowaiver is only applicable to immediate release, solid orally administered dosage forms or suspensions designed to deliver drug to the systemic circulation. Drug products having a narrow therapeutic index are excluded from consideration for a BCS-based biowaiver in this guidance. Fixed-dose combination (FDC) products are eligible for a BCS-based biowaiver when all drug substances contained in the combination drug product

- 34 meet the criteria as defined in sections 2 and 3 of this guidance.
- 35

36 2. BIOPHARMACEUTICS CLASSIFICATION OF THE DRUG SUBSTANCE

BCS-based biowaivers are applicable to drug products where the drug substance exhibits high
solubility and, either high permeability (BCS Class I) or low permeability (BCS Class III).

39

40 A biowaiver is only applicable when the drug substance(s) in test and reference products are 41 identical. For example, a biowaiver is not applicable when the drug substance in the test 42 product is a different salt, ester, isomer, or mixture of isomers from that in the reference 43 product. Pro-drugs may be considered for a BCS-based biowaiver when absorbed as the 44 pro-drug.

45

46 **2.1. Solubility**

A drug substance is classified as highly soluble if the highest single therapeutic dose is completely soluble in 250 ml or less of aqueous media over the pH range of 1.2 - 6.8 at $37 \pm$ 1°C. In cases where the highest single therapeutic dose does not meet this criterion but the highest strength of the reference product is soluble under the aforementioned conditions, additional data should be submitted to justify the BCS-based biowaiver approach.

52

53 The applicant is expected to establish experimentally the equilibrium saturated solubility of 54 the drug substance over the pH range of 1.2 - 6.8 at $37 \pm 1^{\circ}$ C using a shake-flask technique or an alternative method, if justified. At least three buffers within this range, including buffers at 55 pH 1.2, 4.5 and 6.8, should be evaluated. In addition, solubility at the pKa of the drug 56 57 substance should be evaluated if it is within the specified pH range. The pH for each test solution should be measured after the addition of the drug substance and at the end of the 58 equilibrium solubility study to ensure the solubility measurement is conducted under the 59 specified pH. The pH should be adjusted if necessary. The lowest measured solubility over the 60 61 pH range of 1.2 - 6.8 will be used to classify the drug substance.

62

A minimum of three replicate determinations at each solubility condition/pH is necessary to
 demonstrate solubility using a validated stability-indicating method, with appropriate
 compendial references for the media employed.

66

67 In addition, adequate stability of the drug substance in the solubility media should be

- 68 demonstrated. In cases where the drug substance is not stable with >10% degradation over
- 69 the extent of the solubility assessment, solubility cannot be adequately determined and thus
- the drug substance cannot be classified. In this case a BCS-based biowaiver cannot be applied.
- 71 In addition to experimental data, literature data may be provided to substantiate and support

- solubility determinations, keeping in mind that peer reviewed articles may not contain the necessary details of the testing to make a judgement regarding the quality of the studies.
- 74

75 2.2. Permeability

The assessment of permeability should preferentially be based on the extent of absorption
derived from human pharmacokinetic studies, e.g., absolute bioavailability or mass balance.

78

79 High permeability can be concluded when the absolute bioavailability is \geq 85%. High permeability can also be concluded if > 85% of the administered dose is recovered in urine as 80 unchanged (parent drug), or as the sum of parent drug, Phase 1 oxidative and Phase 2 81 82 conjugative metabolites. Regarding metabolites in feces only oxidative and conjugative 83 metabolites can be considered. Metabolites produced through reduction or hydrolysis should not be included, unless it can be demonstrated that they are not produced by microbial action 84 85 within the gastrointestinal tract. Unchanged drug in feces cannot be counted toward the extent 86 of absorption, unless appropriate data supports that the amount of parent drug in feces to be 87 accounted for absorbed drug material is from biliary excretion, intestinal secretion or originates from an unstable metabolite, e.g., glucuronide, sulphate, N-oxide that has been 88 converted back to the parent by the action of microbial organisms. 89

90

Human *in vivo* data derived from published literature (for example, product knowledge and previously published bioavailability studies) may be acceptable, keeping in mind that peer reviewed articles may not contain the necessary details of the testing to make a judgement regarding the quality of the results.

95

96 Permeability can be also assessed by validated and standardized *in vitro* methods using 97 Caco-2 cells(see Annex I). The results from Caco-2 permeability assays should be discussed 98 in the context of available data on human pharmacokinetics. *In vitro* cell permeability assays 99 (Caco-2) used in support of high permeability should be appropriately validated and 100 standardized as outlined in Annex 1. If high permeability is inferred by means of an *in vitro* 101 cell system, permeability independent of active transport should be proven as outlined in 102 Annex I, "Assay Considerations".

103

If high permeability is not demonstrated, the drug substance is considered to have lowpermeability (e.g. BCS class III).

- 106
- 107 Instability in the Gastrointestinal Tract
- 108 If mass balance studies or *in vitro* Caco-2 studies are used to demonstrate high permeability,
- additional data to document the drug's stability in the gastrointestinal tract should be provided,

unless $\geq 85\%$ of the dose is recovered as unchanged drug in urine. Stability in the 110 gastrointestinal tract may be documented using compendial and simulated gastric and 111 intestinal fluids or, with suitable justification, other relevant methods. Drug solutions should 112 be incubated at 37°C for a period that is representative of the in vivo contact of the drug 113 substance with these fluids, i.e., one hour in gastric fluid and three hours in intestinal fluid. 114 Drug concentrations should then be determined using a validated stability indicating assay 115 method. Significant degradation (>10 percent) of a drug in this study could suggest potential 116 117 instability.

118

3. SUPPORT OF THE ELIGIBILITY OF A DRUG PRODUCT FOR A BCS-BASED BIOWAIVER

A drug product is eligible for a BCS-based biowaiver provided that the drug substance(s) 121 satisfy the criteria regarding solubility and permeability (BCS Class I and III), the drug 122 123 product is an immediate-release oral dosage form with systemic action, and the drug product 124 is a dosage form that is pharmaceutically equivalent to the reference product. In cases where the highest single therapeutic dose does not meet the high solubility criterion but the highest 125 strength of the reference product is soluble under the required conditions, BCS-based 126 biowaivers can be supported based on additional data. An example of such additional data is 127 demonstration of dose proportional pharmacokinetics (i.e. AUC and C_{max}) over a dose range 128 129 that includes the highest therapeutic dose.

130

Drug products with buccal or sublingual absorption are not eligible for a BCS-based biowaiver application. As such, an orodispersible product is eligible for a biowaiver application only if there is no buccal or sublingual absorption and the product is labelled to be taken with water only.

135

In order for a drug product to qualify for a BCS-based biowaiver, criteria with respect to the composition (excipients) and *in vitro* dissolution performance of the drug product should be satisfied. The drug product acceptance criteria are described in sections 3.1 and 3.2 below.

139

140 **3.1. Excipients**

Excipient differences between the proposed test and the reference products should be assessed for their potential to affect *in vivo* absorption. This should include consideration of the drug substance properties as well as excipient effects. To be eligible for a BCS-based biowaiver, the applicant should justify why the proposed excipient differences will not affect the absorption profile of the drug substance under consideration, i.e., rate and extent of absorption, using a mechanistic and risk-based approach. The decision tree for performing such an assessment is outlined in Figures 1 and 2 in Annex II.

The possible effects of excipients on aspects of *in vivo* absorption such as solubility, gastrointestinal motility, transit time and intestinal permeability including transporter mechanisms, should be considered. Excipients that may affect absorption include sugar-alcohols, e.g., mannitol, sorbitol, and surfactants, e.g., sodium lauryl sulfate. The risk that a given excipient will affect the absorption of a drug substance should be assessed mechanistically by considering

- 155
 - the amount of excipient used,
- the mechanism by which the excipient may affect absorption,
- 157 158
- absorption properties (rate, extent and mechanism of absorption) of the drug substance.
- 159

160 The amount of excipients that may affect absorption in the test and reference formulations 161 should be addressed during product development, such that excipient changes are kept to a 162 minimum. Small amounts included in the tablet coating or levels below documented 163 thresholds of effect for the specific drug substance are of less concern.

164

By definition, BCS Class I drugs are highly absorbed, and have neither solubility nor 165 permeability limited absorption. Therefore they generally represent a low risk group of 166 compounds in terms of the potential for excipients to affect absorption, compared to other 167 BCS classes. Consideration of excipient effects for BCS ClassI drug products should focus on 168 169 potential changes in the rate or extent of absorption. For example, if it is known that the drug has high permeability due to active uptake, excipients that can inhibit uptake transporters are 170 171 likely to be of concern. For BCS Class I drugs that exhibit slow absorption, the potential fora given excipient to increase absorption rate should also be considered. 172

173

For BCS Class I drugs, qualitative and quantitative differences in excipients are permitted, except for excipients that may affect absorption, which should be qualitatively the same and quantitatively similar, i.e., within \pm 10.0% of the amount of excipient in the reference product.

BCS Class III drug substances are considered to be more susceptible to the effects of excipients. These drugs are poorly permeable and may have site-specific absorption, so there are a greater number of mechanisms through which excipients can affect their absorption than for BCS Class I drugs. For BCS Class III drugs, all of the excipients should be qualitatively the same and quantitatively similar (except for film coating or capsule shell excipients). This is defined in Table 1. Examples of acceptable differences in excipients are shown in Annex II. 185

Table 1: Allowable differences in excipients for drug products containing BCS Class III
 drugs.

Excipient class	Percent of the amount of excipient in the reference	Percent difference relative to core weight (w/w)
Excipients which may affect absorption:	± 10.0%	
All excipients:		
Filler		$\pm 10.0\%$
Disintegrant		
Starch		$\pm 6.0\%$
Other		$\pm 2.0\%$
Binder		$\pm 1.0\%$
Lubricant		
Ca or Mg stearate		$\pm 0.5\%$
Other		$\pm 2.0\%$
Glidant		
Talc		$\pm 2.0\%$
Other		$\pm 0.2\%$
	Total % change permitted:	10.0%

188 Note: Core does not include tablet film coat or capsule shell

189

For FDC formulations containing only BCS Class I drugs, criteria regarding excipients should follow that for a BCS Class I drug. For FDC formulations containing only BCS Class III drugs, or BCS Class I and BCS Class III drugs, criteria regarding excipients should follow that for a BCS Class III drug. This is applicable to FDCs which are pharmaceutically equivalent.

195

196 **3.2.** *In vitro* **Dissolution**

When applying the BCS based biowaiver approach, comparative *in vitro* dissolution tests should be conducted using one batch representative of the proposed commercial manufacturing process for the test product relative to one batch of the reference product. The test product should originate from a batch of at least 1/10 of production scale or 100,000 units, whichever is greater, unless otherwise justified. During a (clinical) development phase, smaller batch sizes may be acceptable, if justified. The comparative *in vitro* dissolution
 experiments should use compendial apparatuses and validated analytical methods.

204

212

The following conditions should be employed in the comparative dissolution studies to characterize the dissolution profile of the product:

- Apparatus: paddle or basket
- Volume of dissolution medium: 900 ml or less (it is recommended to use the volume selected for the QC test)
- Temperature of the dissolution medium: $37 \pm 1^{\circ}C$
- Agitation: paddle apparatus 50 rpm
 - basket apparatus 100 rpm
- At least 12 units of reference and test product should be used for each dissolution profile determination.
- Three buffers: pH 1.2, pH 4.5, and pH 6.8. Pharmacopoeial buffers should be employed. Additional investigation may be required at the pH of minimum solubility (if different from the buffers above). Purified water may be used as an additional dissolution medium in some regions.
- Organic solvents are not acceptable and no surfactants should be added.
- Samples should be filtered during collection
- For gelatin capsules or tablets with gelatin coatings where cross-linking has been demonstrated, the use of enzymes may be acceptable, if appropriately justified.
- 223

When high variability or coning is observed in the paddle apparatus at 50 rpm, the use of the basket apparatus at 100 rpm is recommended. Additionally, use of sinkers in the paddle apparatus to overcome issues such as coning may be considered with justification.

227

To qualify for a BCS-based biowaiver for BCS Class I drug substances both the test product and reference product should display either very rapid (\geq 85 for the mean percent dissolved in \leq 15 minutes) or rapid (\geq 85 for the mean percent dissolved in \leq 30 minutes) and similar *in vitro* dissolution characteristics under all of the defined conditions. In cases where one product has rapid dissolution and the other has very rapid dissolution, statistical similarity of the profiles should be demonstrated as below.

234

For the comparison of dissolution profiles, where applicable, the similarity factor f2 should be estimated by using the following formula:

237 238

 $f2 = 50 \bullet \log \{ [1 + (1/n)\Sigma_{t=1}^{n} (R_t - T_t)^2]^{-0.5} \bullet 100 \}$

In this equation f2 is the similarity factor, n is the number of time points, R(t) is the mean percent reference drug dissolved at time t after initiation of the study; T(t) is the mean percent test drug dissolved at time t after initiation of the study.

243

244 The evaluation of the similarity factor is based on the following conditions:

- A minimum of three time points (zero excluded)
- The time points should be the same for the two products
- Mean of twelve individual values for every time point for each product.
- Not more than one mean value of \geq 85% dissolved for any of the products.
- To allow the use of mean data, the coefficient of variation should not be more than 250 20% at early time-points (up to 10 minutes), and should not be more than 10% at 251 other time points.
- 252

Two dissolution profiles are considered similar when the f2 value is \geq 50. When both test and reference products demonstrate that \geq 85% of the label amount of the drug is dissolved in 15 minutes, comparison with an f2 test is unnecessary and the dissolution profiles are considered similar. In case the coefficient of variation is too high, f2 calculation is considered not accurate and reliable and a conclusion on similarity in dissolution cannot be made.

258

To qualify for a BCS-based biowaiver for BCS Class III drug substances both the test product and reference product should display very rapid (\geq 85 for the mean percent dissolved in \leq 15 minutes) *in vitro* dissolution characteristics under the defined conditions.

262

For FDC formulations, dissolution profiles should meet the criteria for all drug substances in the FDC to be considered. For FDC formulations containing only BCS I drugs, criteria regarding dissolution should follow that for a BCS Class I drug. For FDC formulations containing only BCS Class III drugs, criteria regarding dissolution should follow that for a BCS Class III drug. For FDCs containing both BCS Class I and BCS Class III drugs the dissolution criteria for the applicable BCS class for each component should be applied.

269

For products with more than one strength the BCS approach should be applied for each strength, i.e., it is expected that test and reference product dissolution profiles are compared at each strength.

273

4. DOCUMENTATION

The applicant should provide complete information on the critical quality attributes of the test drug substance and drug product and as much information as possible for the reference product, including, but not limited to: polymorphic form and enantiomeric purity; and any

information on bioavailability or bioequivalence problems with the drug substance or drug product, including literature surveys and applicant derived studies. All study protocols including standards, quality assurance and testing methods should be appropriately detailed and validated according to current regulatory guidance's and policies.

The reporting format should include tabular and graphical presentations showing individual and mean results and summary statistics. The tabular presentation should include standard deviation and coefficient of variation.

The report should include all excipients, their qualitative and, if possible, quantitative differences between the test and reference products.

A full description of the analytical methods employed, including validation, e.g. method linearity, accuracy and precision, should be provided. A detailed description of all test methods andmedia, including test and reference batch information [unit dose (milligram and %), batch number, manufacturing date and batch size where known, expiry date, and any comments] should also be provided. The dissolution report should include a thorough description of experimental settings and analytical methods, including information on the dissolution conditions such as apparatus, de-aeration, filtration during sampling, volume, etc.

In addition, complete information with full description of the methods applied should be provided for the Caco-2 cell permeability assay method, if applicable (see Annex I).

296

297 **5. GLOSSARY**

- 298 AUC: Area under the concentration versus time curve
- 299 BCS: Biopharmaceutics Classification System
- 300 C_{max}: Maximum concentration
- 301 FDC: Fixed-dose combination

302 Pharmaceutically equivalent: Medicinal products containing the same amount of the same 303 active substance(s) in the same dosage forms.

- 304 pKa: Acid dissociation constant at logarithmic scale
- 305 rpm: rotation per minute

307 ANNEX I: Caco-2 CELL PERMEABILITY ASSAY METHOD CONSIDERATIONS

308 Permeability assays employing cultured Caco-2 epithelial cell monolayers derived from a 309 human colon adenocarcinoma cell line are widely used to estimate intestinal drug absorption 310 in humans. Caco-2 cells undergo spontaneous morphological and biochemical enterocytic differentiation, and express cell polarity with an apical brush border, tight intercellular 311 junctions, and several active transporters as in the small intestine. Due to a potential for low 312 313 or absent expression of efflux (e.g., P-gp, BCRP, MRP2) and uptake (e.g., PepT1, OATP2B1, 314 MCT1) transporters, the use of Caco-2 cell assays in support of high permeability for BCS classification is limited to passively transported drugs (for definition see Assay 315 316 Considerations).

317

318 Method validation

319 The suitability of the Caco-2 cell assays for BCS permeability determination should be demonstrated by establishing a rank-order relationship between experimental permeability 320 321 values and the extent of drug absorption in human subjects using zero, low (<50%), moderate (50 - 84%), and high ($\geq 85\%$) permeability model drugs. A sufficient number of model drugs 322 are recommended for the validation to characterize the full permeability range (a minimum 5 323 for each permeability category, high, moderate and low is recommended; examples are 324 provided in Table 1). Further, a sufficient number (minimum of 3) of cell assay replicates 325 should be employed to provide a reliable estimate of drug permeability. The established 326 relationship should permit differentiation between low, moderate and high permeability drugs. 327 328

329 Caco-2 cell monolayer integrity should be confirmed by comparing transepithelial electrical

resistance (TEER) measures and/or other suitable indicators, prior to and after an experiment.

In addition, cell monolayer integrity should be demonstrated by means of compounds withproven zero permeability.

333

Reporting of the method validation should include a list of the selected model drugs along with data on extent of absorption in humans (mean, standard deviation, coefficient of variation) used to establish suitability of the method, permeability values for each model drug (mean, standard deviation, coefficient of variation), permeability class of each model drug, and a plot of the extent of absorption as a function of permeability (mean \pm standard deviation or 95 percent confidence interval) with identification of the high permeability class boundary and selected high permeability internal standard used to classify the test drug substance.

341

In addition, a description of the study method, drug concentrations in the donor fluid,

343 description of the analytical method, equation used to calculate permeability, and where

appropriate, information on efflux potential, e.g., bidirectional transport data should be

345 provided for a known substrate.

346

347 Assay considerations

As noted above, the use of Caco-2 cell assays in support of BCS permeability determination is 348 limited to passively transported drugs. A passive transport mechanism can be inferred when 349 the pharmacokinetics of the drug (assessed as AUC and C_{max} parameters) are dose 350 351 proportional over the relevant clinical dose range. Alternatively, the absence of an active transport mechanism may be verified using a suitable assay system that expresses known 352 efflux transporters, e.g., by demonstrating independence of measured in vitro permeability on 353 initial drug concentration, e.g., 0.01, 0.1, and 1 times the highest strength dissolved in 250 ml, 354 or on transport direction (efflux ratio, i.e., ratio of apparent permeability (P_{app}) between the 355 basolateral-to-apical and apical-to-basolateral directions <2 for the selected drug 356 concentrations). 357

358

Efflux ratio =
$$P_{appBL \rightarrow AP}/P_{appAP \rightarrow BL}$$
.

Functional expression of efflux transporters should be verified by using bidirectional transport studies demonstrating asymmetric permeability of selected efflux transporter substrates, e.g., digoxin, vinblastine, rhodamine 123, at non-saturating concentrations.

362

The test drug substance concentrations used in the permeability studies should be justified. A 363 validated Caco-2 method used for drug permeability determinations should employ conditions 364 established during the validation, and include a moderate and a high permeability model drug 365 as internal standards to demonstrate consistency of the method, i.e., included in the donor 366 fluid along with the test drug. The choice of internal standards should be based on 367 compatibility with the test drug, i.e., they should not exhibit any significant physical, 368 chemical, or permeation interactions. The permeability of the internal standards may be 369 370 determined following evaluation of the test drug in the same monolayers or monolayers in the same plate, when it is not feasible to include internal standards in the same cell culture well as 371 the test drug permeability evaluation. The permeability values of the internal standards should 372 be consistent between different tests, including those conducted during method validation. 373 374 Acceptance criteria should be set for the internal standards and model efflux drug. Mean drug 375 and internal standards recovery at the end of the test should be assessed. For recoveries <80%, a mass balance evaluation should be conducted including measurement of the residual amount 376 377 of drug in the membrane.

378

Evaluation of the test drug permeability for BCS classification may be facilitated by selection of a high permeability internal standard with permeability in close proximity to the moderate/high permeability class boundary. The test drug is considered highly permeable

- 382 when its permeability value is equal to or greater than that of the selected internal standard 383 with high permeability.
- 384
- 385 Information to support high permeability of a test drug substance (mean, standard deviation,
- 386 coefficient of variation) should include permeability data on the test drug substance, the
- 387 internal standards, *in vitro* gastrointestinal stability information, and data supporting passive
- 388 transport mechanism.
- 389

Group	Drug
High Permeability	Antipyrine
$(f_a \ge 85 \text{ percent})$	Caffeine
	Ketoprofen
	Naproxen
	Theophylline
	Metoprolol
	Propranolol
	Carbamazepine
	Phenytoin
	Disopyramide
	Minoxidil
Moderate Permeability	Chlorpheniramine
$(f_a = 50-84 \text{ percent})$	Creatinine
	Terbutaline
	Hydrochlorothiazide
	Enalapril
	Furosemide
	Metformin
	Amiloride
	Atenolol
	Ranitidine
Low Permeability	Famotidine
$(f_a < 50 \text{ percent})$	Nadolol
	Sulpiride
	Lisinopril
	Acyclovir
	Foscarnet
	Mannitol


Table 2. Examples of model drugs for permeability assay method validation

Group	Drug	
	Chlorothiazide	
	Polyethylene glycol 400	
	Enalaprilat	
Zero Permeability	FITC-Dextran	
	Polyethylene glycol 4000	
	Lucifer yellow	
	Inulin	
	Lactulose	
Efflux Substrates	Digoxin	
	Paclitaxel	
	Quinidine	
	Vinblastine	

ANNEX II: FURTHER INFORMATION ON THE ASSESSMENT OF EXCIPIENT 395


DIFFERENCES 396

397 Figure 1. BCS Class I Drug Substances



399





402

403 **EXAMPLES OF ACCEPTABLE DIFFERENCES IN EXCIPIENTS**

404 Example 1: BCS Class I Biowaiver

- 405 The amount of sorbitol (an excipient that affects absorption) in the test formulation is different
- 406 from the reference formulation. The permitted range is 45 mg to 55 mg of sorbitol based on
- 407 the amount in the reference formulation (50 mg \pm 10.0%).
- 408

Component	Amount (mg) reference	Amount (mg) test	
Drug substance	100	100	
Microcrystalline cellulose (filler)	100	95	
HPMC (binder)	10	10	
Talc	5	5	
Sorbitol (filler)	50	55	
Total	265	265	

409

411

412 Example 2: BCS Class III Biowaiver

- 413 The test formulation is qualitatively the same as the reference formulation. The amount of
- 414 sorbitol (an excipient that affects absorption) in the test formulation is different from the
- 415 reference formulation. The permitted range is 9 mg to 11 mg of sorbitol based on the amount
- 416 in the reference formulation ($10 \text{ mg} \pm 10.0\%$). For the other excipients the differences were
- 417 within the criteria provided in Table 1.

	Reference Product		Test Product		Absolute	
Component	Composition (mg)	Proportion relative to core weight (%w/w)	Composition (mg)	Proportion relative to core weight (%w/w)	percent difference relative to core weights	
Drug substance	100	49.3%	100	46.5%		
Lactose monohydrate (filler)	85	41.9%	97	45.1%	3.2%	
Croscarmellose sodium (disintegrant)	6	3.0%	7	3.3%	0.3%	
Magnesium stearate	2	1.0%	2	0.9%	0.1%	
Sorbitol (filler)	10	4.9%	9	4.2%	0.7%	
Total	203	100%	215	100%		
				Total change:	4.3%	